Cachexia and pancreatic cancer: Are there treatment options?

World Journal of Gastroenterology

Volumn 20, Issue 28, 2014, Pages 9361-9373

  Mueller, Tara C ^a   Burmeister, Marc A ^b   Bachmann, Jeannine ^a   Martignoni, Marc E ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Cachexia; Gastrointestinal neoplasms; Nutritional support; Pancreatic neoplasms

Indexed keywords

ACETYLCYSTEINE; ALPHA TOCOPHEROL; ANDROGEN; ANTIOXIDANT; ASCORBIC ACID; BRANCHED CHAIN AMINO ACID; CARNITINE; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOCOSAHEXAENOIC ACID; DRONABINOL; GLUTATHIONE; ICOSAPENTAENOIC ACID; INSULIN; LACTOFERRIN; MIRTAZAPINE; MYOSTATIN; NONSTEROID ANTIINFLAMMATORY AGENT; OLANZAPINE; OMEGA 3 FATTY ACID; PENTOXIFYLLINE; PROGESTERONE; RETINOL; SELECTIVE ANDROGEN RECEPTOR MODULATOR; SOMATOMEDIN; THALIDOMIDE; THIOCTIC ACID; TUMOR NECROSIS FACTOR ANTIBODY; UNINDEXED DRUG; APPETITE STIMULANT;

ANOREXIA; APPETITE; ARTICLE; CACHEXIA; CALORIC INTAKE; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CHRONIC PAIN; DEPRESSION; DIET SUPPLEMENTATION; DIGESTIVE SYSTEM FUNCTION DISORDER; FATIGUE; FOOD INTAKE; HUMAN; INFLAMMATION; INTRAABDOMINAL FAT; KINESIOTHERAPY; LOSS OF APPETITE; MUSCLE ATROPHY; NONHUMAN; NUTRITIONAL SUPPORT; OUTCOME ASSESSMENT; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PANCREAS RESECTION; PARENTERAL NUTRITION; PHYSICAL ACTIVITY; STIMULATION; TOTAL PARENTERAL NUTRITION; COMPLICATION; DIET THERAPY; MULTIMODALITY CANCER THERAPY; NUTRITIONAL STATUS; PALLIATIVE THERAPY; PANCREAS CARCINOMA; PANCREAS TUMOR; PATHOPHYSIOLOGY; PROCEDURES; PSYCHOLOGY; TREATMENT OUTCOME;

APPETITE STIMULANTS; CACHEXIA; CARCINOMA, PANCREATIC DUCTAL; COMBINED MODALITY THERAPY; DIETARY SUPPLEMENTS; HUMANS; NUTRITION THERAPY; NUTRITIONAL STATUS; NUTRITIONAL SUPPORT; PALLIATIVE CARE; PANCREATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 84908869158     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i28.9361     Document Type: Article

References (98)

1. Fearon KC. Cancer cachexia: developing multimodal therapy for a multidimensional problem. Eur J Cancer 2008; 44: 1124-1132 [PMID: 18375115 DOI: 10.1016/j.ejca.2008.02.033]
2. Tuca A, Jimenez-Fonseca P, Gascón P. Clinical evaluation and optimal management of cancer cachexia. Crit Rev Oncol Hematol 2013; 88: 625-636 [PMID: 23953794 DOI: 10.1016/j.critrevonc.2013.07.015]
3. Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, Jatoi A, Loprinzi C, MacDonald N, Mantovani G, Davis M, Muscaritoli M, Ottery F, Radbruch L, Ravasco P, Walsh D, Wilcock A, Kaasa S, Baracos VE. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 2011; 12: 489-495 [PMID: 21296615 DOI: 10.1016/S1470-2045(10)70218-7]
4. Fearon K, Arends J, Baracos V. Understanding the mechanisms and treatment options in cancer cachexia. Nat Rev Clin Oncol 2013; 10: 90-99 [PMID: 23207794 DOI: 10.1038/nrclinonc. 2012.209]
5. Martin L, Birdsell L, Macdonald N, Reiman T, Clandinin MT, McCargar LJ, Murphy R, Ghosh S, Sawyer MB, Baracos VE. Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol 2013; 31: 1539-1547 [PMID: 23530101 DOI: 10.1200/JCO.2012.45.2722]
6. Di Sebastiano KM, Yang L, Zbuk K, Wong RK, Chow T, Koff D, Moran GR, Mourtzakis M. Accelerated muscle and adipose tissue loss may predict survival in pancreatic cancer patients: the relationship with diabetes and anaemia. Br J Nutr 2013; 109: 302-312 [PMID: 23021109 DOI: 10.1017/S0007114512001067]
7. Tan BH, Birdsell LA, Martin L, Baracos VE, Fearon KC. Sarcopenia in an overweight or obese patient is an adverse prognostic factor in pancreatic cancer. Clin Cancer Res 2009; 15: 6973-6979 [PMID: 19887488 DOI: 10.1158/1078-0432. ccr-09-1525]
8. Englesbe MJ, Patel SP, He K, Lynch RJ, Schaubel DE, Harbaugh C, Holcombe SA, Wang SC, Segev DL, Sonnenday CJ. Sarcopenia and mortality after liver transplantation. J Am Coll Surg 2010; 211: 271-278 [PMID: 20670867 DOI: 10.1016/j.jamcollsurg.2010.03.039]
9. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63: 11-30 [PMID: 23335087 DOI: 10.3322/caac.21166]
10. Fearon KC, Baracos VE. Cachexia in pancreatic cancer: new treatment options and measures of success. HPB (Oxford) 2010; 12: 323-324 [PMID: 20590907 DOI: 10.1111/j.1477-2574.2010.00178.x]
11. Wigmore SJ, Plester CE, Richardson RA, Fearon KC. Changes in nutritional status associated with unresectable pancreatic cancer. Br J Cancer 1997; 75: 106-109 [PMID: 9000606]
12. Uomo G, Gallucci F, Rabitti PG. Anorexia-cachexia syndrome in pancreatic cancer: recent development in research and management. JOP 2006; 7: 157-162 [PMID: 16525199]
13. Bachmann J, Büchler MW, Friess H, Martignoni ME. Cachexia in patients with chronic pancreatitis and pancreatic cancer: impact on survival and outcome. Nutr Cancer 2013; 65: 827-833 [PMID: 23909726 DOI: 10.1080/01635581.2013.80 4580]
14. Bachmann J, Ketterer K, Marsch C, Fechtner K, Krakowski-Roosen H, Büchler MW, Friess H, Martignoni ME. Pancreatic cancer related cachexia: influence on metabolism and correlation to weight loss and pulmonary function. BMC Cancer 2009; 9: 255 [PMID: 19635171 DOI: 10.1186/1471-2407-9-255]
15. Bachmann J, Heiligensetzer M, Krakowski-Roosen H, Büchler MW, Friess H, Martignoni ME. Cachexia worsens prognosis in patients with resectable pancreatic cancer. J Gastrointest Surg 2008; 12: 1193-1201 [PMID: 18347879 DOI: 10.1007/s11605-008-0505-z]
16. Pausch T, Hartwig W, Hinz U, Swolana T, Bundy BD, Hackert T, Grenacher L, Büchler MW, Werner J. Cachexia but not obesity worsens the postoperative outcome after pancreatoduodenectomy in pancreatic cancer. Surgery 2012; 152: S81-S88 [PMID: 22770957 DOI: 10.1016/j.surg.2012.05.028]
17. Balentine CJ, Enriquez J, Fisher W, Hodges S, Bansal V, Sansgiry S, Petersen NJ, Berger DH. Intra-abdominal fat predicts survival in pancreatic cancer. J Gastrointest Surg 2010; 14: 1832-1837 [PMID: 20725799 DOI: 10.1007/s11605-010-1297-5]
18. Martignoni ME, Dimitriu C, Bachmann J, Krakowski-Rosen H, Ketterer K, Kinscherf R, Friess H. Liver macrophages contribute to pancreatic cancer-related cachexia. Oncol Rep 2009; 21: 363-369 [PMID: 19148509]
19. Martignoni ME, Kunze P, Hildebrandt W, Künzli B, Berberat P, Giese T, Klöters O, Hammer J, Büchler MW, Giese NA, Friess H. Role of mononuclear cells and inflammatory cytokines in pancreatic cancer-related cachexia. Clin Cancer Res 2005; 11: 5802-5808 [PMID: 16115919 DOI: 10.1158/1078-0432.ccr-05-0185]
20. Fearon KC, Glass DJ, Guttridge DC. Cancer cachexia: mediators, signaling, and metabolic pathways. Cell Metab 2012; 16: 153-166 [PMID: 22795476 DOI: 10.1016/j.cmet.2012.06.011]
21. Glass DJ. Signaling pathways perturbing muscle mass. Curr Opin Clin Nutr Metab Care 2010; 13: 225-229 [PMID: 20397318]
22. Ebrahimi B, Tucker SL, Li D, Abbruzzese JL, Kurzrock R. Cytokines in pancreatic carcinoma: correlation with phenotypic characteristics and prognosis. Cancer 2004; 101: 2727-2736 [PMID: 15526319 DOI: 10.1002/cncr.20672]
23. Barber MD, Powell JJ, Lynch SF, Fearon KC, Ross JA. A polymorphism of the interleukin-1 beta gene influences survival in pancreatic cancer. Br J Cancer 2000; 83: 1443-1447 [PMID: 11076651 DOI: 10.1054/bjoc.2000.1479]
24. Davidson W, Ash S, Capra S, Bauer J. Weight stabilisation is associated with improved survival duration and quality of life in unresectable pancreatic cancer. Clin Nutr 2004; 23: 239-247 [PMID: 15030964 DOI: 10.1016/j.clnu.2003.07.001]
25. Stathis A, Moore MJ. Advanced pancreatic carcinoma: current treatment and future challenges. Nat Rev Clin Oncol 2010; 7: 163-172 [PMID: 20101258 DOI: 10.1038/nrclinonc. 2009.236]
26. Fazal S, Saif MW. Supportive and palliative care of pancreatic cancer. JOP 2007; 8: 240-253 [PMID: 17356251]
27. Bozzetti F, Arends J, Lundholm K, Micklewright A, Zurcher G, Muscaritoli M. ESPEN Guidelines on Parenteral Nutrition: non-surgical oncology. Clin Nutr 2009; 28: 445-454 [PMID: 19477052 DOI: 10.1016/j.clnu.2009.04.011]
28. Morley JE. Calories and cachexia. Curr Opin Clin Nutr Metab Care 2009; 12: 607-610 [PMID: 19741513 DOI: 10.1097/MCO.0b013e328331e9ce]
29. Bauer J, Capra S, Battistutta D, Davidson W, Ash S. Compliance with nutrition prescription improves outcomes in patients with unresectable pancreatic cancer. Clin Nutr 2005; 24: 998-1004 [PMID: 16140426 DOI: 10.1016/j.clnu.2005.07.002]
30. Bauer JD, Capra S. Nutrition intervention improves outcomes in patients with cancer cachexia receiving chemotherapy-a pilot study. Support Care Cancer 2005; 13: 270-274 [PMID: 15583950 DOI: 10.1007/s00520-004-0746-7]
31. Pelzer U, Arnold D, Gövercin M, Stieler J, Doerken B, Riess H, Oettle H. Parenteral nutrition support for patients with pancreatic cancer. Results of a phase II study. BMC Cancer 2010; 10: 86 [PMID: 20214798 DOI: 10.1186/1471-2407-10-86]
32. Colomer R, Moreno-Nogueira JM, García-Luna PP, García-Peris P, García-de-Lorenzo A, Zarazaga A, Quecedo L, del Llano J, Usán L, Casimiro C. N-3 fatty acids, cancer and cachexia: a systematic review of the literature. Br J Nutr 2007; 97: 823-831 [PMID: 17408522 DOI: 10.1017/S000711450765795X]
33. Brown TT, Zelnik DL, Dobs AS. Fish oil supplementation in the treatment of cachexia in pancreatic cancer patients. Int J Gastrointest Cancer 2003; 34: 143-150 [PMID: 15361649 DOI: 10.1385/IJGC:]
34. Barber MD, Ross JA, Voss AC, Tisdale MJ, Fearon KC. The effect of an oral nutritional supplement enriched with fish oil on weight-loss in patients with pancreatic cancer. Br J Cancer 1999; 81: 80-86 [PMID: 10487616 DOI: 10.1038/sj.bjc.6690654]
35. Ries A, Trottenberg P, Elsner F, Stiel S, Haugen D, Kaasa S, Radbruch L. A systematic review on the role of fish oil for the treatment of cachexia in advanced cancer: an EPCRC cachexia guidelines project. Palliat Med 2012; 26: 294-304 [PMID: 21865295 DOI: 10.1177/0269216311418709]
36. Shirota T, Haji S, Yamasaki M, Iwasaki T, Hidaka T, Takeyama Y, Shiozaki H, Ohyanagi H. Apoptosis in human pancreatic cancer cells induced by eicosapentaenoic acid. Nutrition 2005; 21: 1010-1017 [PMID: 16157238 DOI: 10.1016/j.nut.2004.12.013]
37. Szefel J, Kruszewski WJ, Ciesielski M, Szajewski M, Kawecki K, Aleksandrowicz-Wrona E, Jankun J, Lysiak-Szydłowska W. L-carnitine and cancer cachexia. I. L-carnitine distribution and metabolic disorders in cancer cachexia. Oncol Rep 2012; 28: 319-323 [PMID: 22562434 DOI: 10.3892/or.2012.1804]
38. Silvério R, Laviano A, Rossi Fanelli F, Seelaender M. l-carnitine and cancer cachexia: Clinical and experimental aspects. J Cachexia Sarcopenia Muscle 2011; 2: 37-44 [PMID: 21475677 DOI: 10.1007/s13539-011-0017-7]
39. Busquets S, Serpe R, Toledo M, Betancourt A, Marmonti E, Orpí M, Pin F, Capdevila E, Madeddu C, López-Soriano FJ, Mantovani G, Macciò A, Argilés JM. L-Carnitine: an adequate supplement for a multi-targeted anti-wasting therapy in cancer. Clin Nutr 2012; 31: 889-895 [PMID: 22608917 DOI: 10.1016/j.clnu.2012.03.005]
40. Kraft M, Kraft K, Gärtner S, Mayerle J, Simon P, Weber E, Schütte K, Stieler J, Koula-Jenik H, Holzhauer P, Gröber U, Engel G, Müller C, Feng YS, Aghdassi A, Nitsche C, Malfertheiner P, Patrzyk M, Kohlmann T, Lerch MM. L-Carnitine supplementation in advanced pancreatic cancer (CARPAN)-a randomized multicentre trial. Nutr J 2012; 11: 52 [PMID: 22824168 DOI: 10.1186/1475-2891-11-52]
41. Macciò A, Madeddu C, Mantovani G. Current pharmacotherapy options for cancer anorexia and cachexia. Expert Opin Pharmacother 2012; 13: 2453-2472 [PMID: 23072481 DOI: 10.1517/14656566.2012.734297]
42. Mantovani G, Madeddu C, Macciò A, Gramignano G, Lusso MR, Massa E, Astara G, Serpe R. Cancer-related anorexia/cachexia syndrome and oxidative stress: an innovative approach beyond current treatment. Cancer Epidemiol Biomarkers Prev 2004; 13: 1651-1659 [PMID: 15466983]
43. Mantovani G, Madeddu C, Macciò A. Cachexia and oxidative stress in cancer: an innovative therapeutic management. Curr Pharm Des 2012; 18: 4813-4818 [PMID: 22632861]
44. Mantovani G, Macciò A, Madeddu C, Mura L, Gramignano G, Lusso MR, Murgia V, Camboni P, Ferreli L, Mocci M, Massa E. The impact of different antioxidant agents alone or in combination on reactive oxygen species, antioxidant enzymes and cytokines in a series of advanced cancer patients at different sites: correlation with disease progression. Free Radic Res 2003; 37: 213-223 [PMID: 12653210]
45. Del Fabbro E, Dev R, Hui D, Palmer L, Bruera E. Effects of melatonin on appetite and other symptoms in patients with advanced cancer and cachexia: a double-blind placebo-controlled trial. J Clin Oncol 2013; 31: 1271-1276 [PMID: 23439759 DOI: 10.1200/jco.2012.43.6766]
46. Eley HL, Russell ST, Tisdale MJ. Effect of branched-chain amino acids on muscle atrophy in cancer cachexia. Biochem J 2007; 407: 113-120 [PMID: 17623010 DOI: 10.1042/BJ20070651]
47. Peters SJ, van Helvoort A, Kegler D, Argilès JM, Luiking YC, Laviano A, van Bergenhenegouwen J, Deutz NE, Haagsman HP, Gorselink M, van Norren K. Dose-dependent effects of leucine supplementation on preservation of muscle mass in cancer cachectic mice. Oncol Rep 2011; 26: 247-254 [PMID: 21503587 DOI: 10.3892/or.2011.1269]
48. Berk L, James J, Schwartz A, Hug E, Mahadevan A, Samuels M, Kachnic L. A randomized, double-blind, placebo-controlled trial of a beta-hydroxyl beta-methyl butyrate, glutamine, and arginine mixture for the treatment of cancer cachexia (RTOG 0122). Support Care Cancer 2008; 16: 1179-1188 [PMID: 18293016 DOI: 10.1007/s00520-008-0403-7]
49. May PE, Barber A, D'Olimpio JT, Hourihane A, Abumrad NN. Reversal of cancer-related wasting using oral supplementation with a combination of beta-hydroxy-beta-methylbutyrate, arginine, and glutamine. Am J Surg 2002; 183: 471-479 [PMID: 11975938]
50. Macciò A, Madeddu C, Gramignano G, Mulas C, Sanna E, Mantovani G. Efficacy and safety of oral lactoferrin supplementation in combination with rHuEPO-beta for the treatment of anemia in advanced cancer patients undergoing chemotherapy: open-label, randomized controlled study. Oncologist 2010; 15: 894-902 [PMID: 20647390 DOI: 10.1634/theoncologist.2010-0020]
51. Harle L, Brown T, Laheru D, Dobs AS. Omega-3 fatty acids for the treatment of cancer cachexia: issues in designing clinical trials of dietary supplements. J Altern Complement Med 2005; 11: 1039-1046 [PMID: 16398596 DOI: 10.1089/acm.2005.11.1039]
52. Madeddu C, Mantovani G. An update on promising agents for the treatment of cancer cachexia. Curr Opin Support Palliat Care 2009; 3: 258-262 [PMID: 19667995 DOI: 10.1097/SPC.0b013e3283311c6f]
53. Strasser F, Luftner D, Possinger K, Ernst G, Ruhstaller T, Meissner W, Ko YD, Schnelle M, Reif M, Cerny T. Comparison of orally administered cannabis extract and delta- 9-tetrahydrocannabinol in treating patients with cancerrelated anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group. J Clin Oncol 2006; 24: 3394-3400 [PMID: 16849753 DOI: 10.1200/JCO.2005.05.1847]
54. Garcia JM, Friend J, Allen S. Therapeutic potential of anamorelin, a novel, oral ghrelin mimetic, in patients with cancerrelated cachexia: a multicenter, randomized, double-blind, crossover, pilot study. Support Care Cancer 2013; 21: 129-137 [PMID: 22699302 DOI: 10.1007/s00520-012-1500-1]
55. Fujitsuka N, Asakawa A, Amitani H, Hattori T, Inui A. Efficacy of ghrelin in cancer cachexia: clinical trials and a novel treatment by rikkunshito. Crit Rev Oncog 2012; 17: 277-284 [PMID: 22831158]
56. Neary NM, Small CJ, Wren AM, Lee JL, Druce MR, Palmieri C, Frost GS, Ghatei MA, Coombes RC, Bloom SR. Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, placebo-controlled trial. J Clin Endocrinol Metab 2004; 89: 2832-2836 [PMID: 15181065 DOI: 10.1210/jc.2003-031768]
57. Garcia JM, Polvino WJ. Effect on body weight and safety of RC-1291, a novel, orally available ghrelin mimetic and growth hormone secretagogue: results of a phase I, randomized, placebo-controlled, multiple-dose study in healthy volunteers. Oncologist 2007; 12: 594-600 [PMID: 17522248 DOI: 10.1634/theoncologist.12-5-594]
58. Kast RE, Foley KF. Cancer chemotherapy and cachexia: mirtazapine and olanzapine are 5-HT3 antagonists with good antinausea effects. Eur J Cancer Care (Engl) 2007; 16: 351-354 [PMID: 17587360 DOI: 10.1111/j.1365-2354.2006.00760.x]
59. Navari RM, Brenner MC. Treatment of cancer-related anorexia with olanzapine and megestrol acetate: a randomized trial. Support Care Cancer 2010; 18: 951-956 [PMID: 19756773 DOI: 10.1007/s00520-009-0739-7]
60. Bossola M, Pacelli F, Tortorelli A, Doglietto GB. Cancer cachexia: it's time for more clinical trials. Ann Surg Oncol 2007; 14: 276-285 [PMID: 17094025 DOI: 10.1245/s10434-006-9179-5]
61. Ruiz Garcia V, López-Briz E, Carbonell Sanchis R, Gonzalvez Perales JL, Bort-Marti S. Megestrol acetate for treatment of anorexia-cachexia syndrome. Cochrane Database Syst Rev 2013; 3: CD004310 [PMID: 23543530 DOI: 10.1002/14651858.CD004310.pub3]
62. Yennurajalingam S, Frisbee-Hume S, Palmer JL, Delgado-Guay MO, Bull J, Phan AT, Tannir NM, Litton JK, Reddy A, Hui D, Dalal S, Massie L, Reddy SK, Bruera E. Reduction of cancer-related fatigue with dexamethasone: a doubleblind, randomized, placebo-controlled trial in patients with advanced cancer. J Clin Oncol 2013; 31: 3076-3082 [PMID: 23897970 DOI: 10.1200/JCO.2012.44.4661]
63. Trobec K, von Haehling S, Anker SD, Lainscak M. Growth hormone, insulin-like growth factor 1, and insulin signaling-a pharmacological target in body wasting and cachexia. J Cachexia Sarcopenia Muscle 2011; 2: 191-200 [PMID: 22207907 DOI: 10.1007/s13539-011-0043-5]
64. Gullett NP, Hebbar G, Ziegler TR. Update on clinical trials of growth factors and anabolic steroids in cachexia and wasting. Am J Clin Nutr 2010; 91: 1143S-1147S [PMID: 20164318 DOI: 10.3945/ajcn.2010.28608E]
65. Orr R, Fiatarone Singh M. The anabolic androgenic steroid oxandrolone in the treatment of wasting and catabolic disorders: review of efficacy and safety. Drugs 2004; 64: 725-750 [PMID: 15025546]
66. Vanchieri C. Cachexia in cancer: is it treatable at the molecular level? J Natl Cancer Inst 2010; 102: 1694-1697 [PMID: 21060062 DOI: 10.1093/jnci/djq480]
67. Zilbermint MF, Dobs AS. Nonsteroidal selective androgen receptor modulator Ostarine in cancer cachexia. Future Oncol 2009; 5: 1211-1220 [PMID: 19852734 DOI: 10.2217/fon.09.106]
68. Dobs AS, Boccia RV, Croot CC, Gabrail NY, Dalton JT, Hancock ML, Johnston MA, Steiner MS. Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial. Lancet Oncol 2013; 14: 335-345 [PMID: 23499390 DOI: 10.1016/S1470-2045(13)70055-X]
69. Fearon KH. Selective androgen receptor modulators in cancer cachexia? Lancet Oncol 2013; 14: 271-272 [PMID: 23499391 DOI: 10.1016/S1470-2045(13)70068-8]
70. Lundholm K, Daneryd P, Körner U, Hyltander A, Bosaeus I. Evidence that long-term COX-treatment improves energy homeostasis and body composition in cancer patients with progressive cachexia. Int J Oncol 2004; 24: 505-512 [PMID: 14767534]
71. Wigmore SJ, Falconer JS, Plester CE, Ross JA, Maingay JP, Carter DC, Fearon KC. Ibuprofen reduces energy expenditure and acute-phase protein production compared with placebo in pancreatic cancer patients. Br J Cancer 1995; 72: 185-188 [PMID: 7541236]
72. Solheim TS, Fearon KC, Blum D, Kaasa S. Non-steroidal anti-inflammatory treatment in cancer cachexia: a systematic literature review. Acta Oncol 2013; 52: 6-17 [PMID: 23020528 DOI: 10.3109/0284186X.2012.724536]
73. Mantovani G, Macciò A, Madeddu C, Serpe R, Antoni G, Massa E, Dessì M, Panzone F. Phase II nonrandomized study of the efficacy and safety of COX-2 inhibitor celecoxib on patients with cancer cachexia. J Mol Med (Berl) 2010; 88: 85-92 [PMID: 19802504 DOI: 10.1007/s00109-009-0547-z]
74. Penna F, Minero VG, Costamagna D, Bonelli G, Baccino FM, Costelli P. Anti-cytokine strategies for the treatment of cancer-related anorexia and cachexia. Expert Opin Biol Ther 2010; 10: 1241-1250 [PMID: 20594117 DOI: 10.1517/14712598. 2010.503773]
75. Gordon JN, Trebble TM, Ellis RD, Duncan HD, Johns T, Goggin PM. Thalidomide in the treatment of cancer cachexia: a randomised placebo controlled trial. Gut 2005; 54: 540-545 [PMID: 15753541 DOI: 10.1136/gut.2004.047563]
76. Reid J, Mills M, Cantwell M, Cardwell CR, Murray LJ, Donnelly M. Thalidomide for managing cancer cachexia. Cochrane Database Syst Rev 2012; 4: CD008664 [PMID: 22513961 DOI: 10.1002/14651858.CD008664.pub2]
77. Goldberg RM, Loprinzi CL, Mailliard JA, O'Fallon JR, Krook JE, Ghosh C, Hestorff RD, Chong SF, Reuter NF, Shanahan TG. Pentoxifylline for treatment of cancer anorexia and cachexia? A randomized, double-blind, placebo-controlled trial. J Clin Oncol 1995; 13: 2856-2859 [PMID: 7595749]
78. Jatoi A, Dakhil SR, Nguyen PL, Sloan JA, Kugler JW, Rowland KM, Soori GS, Wender DB, Fitch TR, Novotny PJ, Loprinzi CL. A placebo-controlled double blind trial of etanercept for the cancer anorexia/weight loss syndrome: results from N00C1 from the North Central Cancer Treatment Group. Cancer 2007; 110: 1396-1403 [PMID: 17674351 DOI: 10.1002/cncr.22944]
79. Wiedenmann B, Malfertheiner P, Friess H, Ritch P, Arseneau J, Mantovani G, Caprioni F, Van Cutsem E, Richel D, De Witte M, Qi M, Robinson D, Zhong B, De Boer C, Lu JD, Prabhakar U, Corringham R, Von Hoff D. A multicenter, phase II study of infliximab plus gemcitabine in pancreatic cancer cachexia. J Support Oncol 2008; 6: 18-25 [PMID: 18257397]
80. Yeh KY, Li YY, Hsieh LL, Lu CH, Chou WC, Liaw CC, Tang RP, Liao SK. Analysis of the effect of serum interleukin-6 (IL-6) and soluble IL-6 receptor levels on survival of patients with colorectal cancer. Jpn J Clin Oncol 2010; 40: 580-587 [PMID: 20194250 DOI: 10.1093/jjco/hyq010]
81. Krzystek-Korpacka M, Matusiewicz M, Diakowska D, Grabowski K, Blachut K, Kustrzeba-Wojcicka I, Banas T. Impact of weight loss on circulating IL-1, IL-6, IL-8, TNF-alpha, VEGF-A, VEGF-C and midkine in gastroesophageal cancer patients. Clin Biochem 2007; 40: 1353-1360 [PMID: 17931612 DOI: 10.1016/j.clinbiochem.2007.07.013]
82. Kuroda K, Nakashima J, Kanao K, Kikuchi E, Miyajima A, Horiguchi Y, Nakagawa K, Oya M, Ohigashi T, Murai M. Interleukin 6 is associated with cachexia in patients with prostate cancer. Urology 2007; 69: 113-117 [PMID: 17270630 DOI: 10.1016/j.urology.2006.09.039]
83. Iwase S, Murakami T, Saito Y, Nakagawa K. Steep elevation of blood interleukin-6 (IL-6) associated only with late stages of cachexia in cancer patients. Eur Cytokine Netw 2004; 15: 312-316 [PMID: 15627639]
84. Wigmore SJ, Fearon KC, Sangster K, Maingay JP, Garden OJ, Ross JA. Cytokine regulation of constitutive production of interleukin-8 and -6 by human pancreatic cancer cell lines and serum cytokine concentrations in patients with pancreatic cancer. Int J Oncol 2002; 21: 881-886 [PMID: 12239630]
85. Bayliss TJ, Smith JT, Schuster M, Dragnev KH, Rigas JR. A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancer. Expert Opin Biol Ther 2011; 11: 1663-1668 [PMID: 21995322 DOI: 10.1517/14712598.2011.627850]
86. Lee SJ, Glass DJ. Treating cancer cachexia to treat cancer. Skelet Muscle 2011; 1: 2 [PMID: 21798080 DOI: 10.1186/2044-5040-1-2]
87. Tisdale MJ. Reversing cachexia. Cell 2010; 142: 511-512 [PMID: 20723750 DOI: 10.1016/j.cell.2010.08.004]
88. Adigun AQ, Ajayi AA. The effects of enalapril-digoxin-diuretic combination therapy on nutritional and anthropometric indices in chronic congestive heart failure: preliminary findings in cardiac cachexia. Eur J Heart Fail 2001; 3: 359-363 [PMID: 11378008]
89. Schanze N, Springer J. Evidence for an effect of ACE inhibitors on cancer cachexia. J Cachexia Sarcopenia Muscle 2012; 3: 139 [PMID: 22639062 DOI: 10.1007/s13539-012-0072-8]
90. Mantovani G, Macciò A, Madeddu C, Serpe R, Massa E, Dessì M, Panzone F, Contu P. Randomized phase III clinical trial of five different arms of treatment in 332 patients with cancer cachexia. Oncologist 2010; 15: 200-211 [PMID: 20156909 DOI: 10.1634/theoncologist.2009-0153]
91. Macciò A, Madeddu C, Gramignano G, Mulas C, Floris C, Sanna E, Cau MC, Panzone F, Mantovani G. A randomized phase III clinical trial of a combined treatment for cachexia in patients with gynecological cancers: evaluating the impact on metabolic and inflammatory profiles and quality of life. Gynecol Oncol 2012; 124: 417-425 [PMID: 22198049 DOI: 10.1016/j.ygyno.2011.12.435]
92. Madeddu C, Dessì M, Panzone F, Serpe R, Antoni G, Cau MC, Montaldo L, Mela Q, Mura M, Astara G, Tanca FM, Macciò A, Mantovani G. Randomized phase III clinical trial of a combined treatment with carnitine + celecoxib ± megestrol acetate for patients with cancer-related anorexia/cachexia syndrome. Clin Nutr 2012; 31: 176-182 [PMID: 22047681 DOI: 10.1016/j.clnu.2011.10.005]
93. Tsoli M, Robertson G. Cancer cachexia: malignant inflammation, tumorkines, and metabolic mayhem. Trends Endocrinol Metab 2013; 24: 174-183 [PMID: 23201432 DOI: 10.1016/j.tem.2012.10.006]
94. Fearon KC. The 2011 ESPEN Arvid Wretlind lecture: cancer cachexia: the potential impact of translational research on patient-focused outcomes. Clin Nutr 2012; 31: 577-582 [PMID: 22824237 DOI: 10.1016/j.clnu.2012.06.012]
95. Lundholm K, Körner U, Gunnebo L, Sixt-Ammilon P, Fouladiun M, Daneryd P, Bosaeus I. Insulin treatment in cancer cachexia: effects on survival, metabolism, and physical functioning. Clin Cancer Res 2007; 13: 2699-2706 [PMID: 17473202 DOI: 10.1158/1078-0432.ccr-06-2720]
96. Baldwin C, Spiro A, Ahern R, Emery PW. Oral nutritional interventions in malnourished patients with cancer: a systematic review and meta-analysis. J Natl Cancer Inst 2012; 104: 371-385 [PMID: 22345712 DOI: 10.1093/jnci/djr556]
97. Baracos VE. Clinical trials of cancer cachexia therapy, now and hereafter. J Clin Oncol 2013; 31: 1257-1258 [PMID: 23439747 DOI: 10.1200/jco.2012.48.3149]
98. Argilés JM, Busquets S, López-Soriano FJ, Costelli P, Penna F. Are there any benefits of exercise training in cancer cachexia? J Cachexia Sarcopenia Muscle 2012; 3: 73-76 [PMID: 22565649 DOI: 10.1007/s13539-012-0067-5]